Photodynamic therapy: shedding light on restenosis
Open Access
- 1 December 2001
- Vol. 86 (6) , 612-618
- https://doi.org/10.1136/heart.86.6.612
Abstract
The major limitation of the long term success of percutaneous coronary interventions is the development of restenosis, which occurs in 30–50% of patients within six months.1 2 Restenosis is the result of a complex pathophysiological process in the arterial wall in response to balloon dilatation or stent insertion. For many years the hallmark of this response to injury was considered to be the development of intimal hyperplasia resulting from the proliferation and migration of smooth muscle cells from the arterial media.3More recently, it has become clear that this is not the only factor involved. Other key aspects in the development of the restenotic lesion are the extracellular matrix, elastic vessel recoil, and arterial remodelling.4 While our understanding of the processes induced by balloon injury has improved, treatment strategies to limit this have been disappointing in clinical practice.5Stenting, which is now used in up to 80% of all coronary interventional procedures, has almost eliminated problems from elastic recoil and has reduced restenosis rates, but neointimal hyperplasia around stent struts can still lead to in-stent restenosis.6 Intracoronary brachytherapy is one technique that has proved promising in the prevention of restenosis using either catheter based systems for radiation delivery or radioactive stents.7 Concerns have been expressed about late thrombotic occlusion after brachytherapy.8 However, the prolonged use of antiplatelet drugs may control this problem. Brachytherapy is probably the best option for treating restenosis currently available. Nevertheless, it would be attractive to find a method of preventing restenosis after percutaneous intervention that does not involve ionising radiation or prolonged drug treatment. Photodynamic therapy (PDT), which in contrast to brachytherapy uses non-ionising radiation, is emerging as another possible strategy. PDT involves the interaction of a photosensitising drug, light, and tissue oxygen9 (fig 1). Photosensitising agents, many …Keywords
This publication has 49 references indexed in Scilit:
- Photodynamic Therapy Inhibits the Injury-induced Fibrotic Response of Vascular Smooth Muscle CellsEuropean Journal of Vascular and Endovascular Surgery, 1999
- Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related proceduresProgress in Cardiovascular Diseases, 1997
- Local Photodynamic Therapy Reduces Tissue Hyperplasia in an Experimental Restenosis ModelPhotochemistry and Photobiology, 1996
- In vitro AND in vivo UPTAKE OF BENZOPORPHYRIN DERIVATIVE INTO HUMAN AND MINISWINE ATHEROSCLEROTIC PLAQUEPhotochemistry and Photobiology, 1993
- HOW DOES PHOTODYNAMIC THERAPY WORK?Photochemistry and Photobiology, 1992
- Responses of cultured smooth muscle cells from human nonatherosclerotic arteries and primary stenosing lesions after photoradiation: Implications for photodynamic therapy of vascular stenosesJournal of the American College of Cardiology, 1990
- Effect of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbitsThe American Journal of Cardiology, 1985
- PORPHYRIN ACCUMULATION BY ATHEROMATOUS PLAQUES OF THE AORTAPhotochemistry and Photobiology, 1984
- A controlled trial of propafenone for treatment of frequent and repetitive ventricular premature complexesThe American Journal of Cardiology, 1983
- Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative.Journal of Clinical Investigation, 1983